These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23998856)

  • 41. Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead.
    Kallinen LM; Hauser RG; Lee KW; Almquist AK; Katsiyiannis WT; Tang CY; Melby DP; Gornick CC
    Heart Rhythm; 2008 Jun; 5(6):775-9. PubMed ID: 18534361
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ICD and neuromodulation devices: is peaceful coexistence possible?
    Molon G; Perrone C; Maines M; Costa A; Comisso J; Boi A; Moro E; Vergara G; Barbieri E
    Pacing Clin Electrophysiol; 2011 Jun; 34(6):690-3. PubMed ID: 21303391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inappropriate implantable cardioverter-defibrillator shocks and signal jammers: first report of a new interference.
    Amasyali B; Kilic A
    Int J Cardiol; 2014 Oct; 176(3):e96-7. PubMed ID: 25125021
    [No Abstract]   [Full Text] [Related]  

  • 44. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Electrical failure of an ICD lead due to a presumed insulation defect only diagnosed by a maximum output shock.
    Goldstein MA; Badri M; Kocovic D; Kowey PR
    Pacing Clin Electrophysiol; 2013 Sep; 36(9):1068-71. PubMed ID: 23731252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ablation of atrial fibrillation in Brugada syndrome patients with an implantable cardioverter defibrillator to prevent inappropriate shocks resulting from rapid atrial fibrillation.
    Sairaku A; Yoshida Y; Nakano Y; Kihara Y
    Int J Cardiol; 2013 Oct; 168(6):5273-6. PubMed ID: 23988302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inappropriate discharges from an intravenous implantable cardioverter defibrillator due to T-wave oversensing.
    Washizuka T; Chinushi M; Kasai H; Watanabe H; Tagawa M; Hosaka Y; Abe A; Aizawa Y
    Jpn Circ J; 2001 Jul; 65(7):685-7. PubMed ID: 11446507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implantable cardioverter defibrillators and their role in heart failure progression.
    Cevik C; Perez-Verdia A; Nugent K
    Europace; 2009 Jun; 11(6):710-5. PubMed ID: 19357142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches.
    Borne RT; Varosy PD; Masoudi FA
    JAMA Intern Med; 2013 May; 173(10):859-65. PubMed ID: 23546173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: a substudy of the ECOST trial.
    Guédon-Moreau L; Kouakam C; Klug D; Marquié C; Brigadeau F; Boulé S; Blangy H; Lacroix D; Clémenty J; Sadoul N; Kacet S
    J Cardiovasc Electrophysiol; 2014 Jul; 25(7):763-70. PubMed ID: 24602062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate.
    Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic significance of atrial arrhythmias in a primary prevention ICD population.
    van Gelder IC; Phan HM; Wilkoff BL; Brown ML; Rogers T; Peterson BJ; Birgersdotter-Green UM
    Pacing Clin Electrophysiol; 2011 Sep; 34(9):1070-9. PubMed ID: 21605131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic importance of distressed (Type D) personality and shocks in patients with an implantable cardioverter defibrillator.
    Denollet J; Tekle FB; Pedersen SS; van der Voort PH; Alings M; van den Broek KC
    Int J Cardiol; 2013 Sep; 167(6):2705-9. PubMed ID: 22809538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Late complications of electrotherapy - a clinical analysis of indications for transvenous removal of endocardial leads: a single centre experience.
    Polewczyk A; Kutarski A; Tomaszewski A; Polewczyk M; Janion M
    Kardiol Pol; 2013; 71(4):366-72. PubMed ID: 23788342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Re: "Strategy to eliminate inappropriate shocks secondary to T-wave oversensing in a biventricular ICD".
    Alsheikh T
    Pacing Clin Electrophysiol; 2009 Jul; 32(7):963; author reply 963. PubMed ID: 19572881
    [No Abstract]   [Full Text] [Related]  

  • 57. Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up.
    Mönnig G; Köbe J; Löher A; Wasmer K; Milberg P; Zellerhoff S; Pott C; Zumhagen S; Radu R; Scheld HH; Haverkamp W; Schulze-Bahr E; Eckardt L
    Europace; 2012 Mar; 14(3):396-401. PubMed ID: 21979994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An unusual mechanism causing inappropriate implantable cardioverter defibrillator shocks: transient reduction in R-wave amplitude.
    Baranchuk A; Ribas S; Divakaramenon S; Morillo CA
    Europace; 2007 Aug; 9(8):694-6. PubMed ID: 17478463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-determinable defibrillation threshold and inefficacy of implantable cardioverter/defibrillator shocks due to defective connections of the defibrillator lead terminals in the device header port.
    Maagh P; Trappe HJ; Meissner A
    Europace; 2007 Dec; 9(12):1161-2. PubMed ID: 17913694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ivabradine for the prevention of inappropriate shocks due to sinus tachycardia in patients with an implanted cardioverter defibrillator.
    Adler A; Rosso R; Meir I; Viskin S
    Europace; 2013 Mar; 15(3):362-5. PubMed ID: 23118003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.